Prostate - Bone Targeted Therapies
Published: Thu Oct 13, 2011 Updated:Fri Oct 21, 2011
-
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial
MR Smith et al; January 7, 2012; doi:10.1016/S0140-6736(11)61226-9
-
Bone scan index: A quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
ER Dennis; January 9, 2012; JCO.2011.36.5791
-
Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma
SP Kim et al; January 3, 2012; DOI: 10.1002/cncr.26695
-
Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
L Albiges et al; January 9, 2012; doi: 10.1200/JCO.2011.37.2516
-
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
MR Smith et al; November 16, 2011; doi:10.1016/S0140-6736(11)61226-9
-
Prostate Cancer Biomarkers: Research Updates at AUA Annual Meeting
P Eastman et al, Sep 10, 2011; doi: 10.1097/01.COT.0000405392.63562.8f
-
Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents
ES Antonaraki et al, Aug 25, 2011; DOI: 10.1002/cncr.26437
-
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Read a review of this article by Dr. Lori Wood
K Fizazi et al, Lancet. Mar 5 2011; 377(9768):813-22
-
Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer
F Saad et al, J Natl Cancer Inst. Jun 2004; 96(11):879-82
-
Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men with Metastatic Prostate Cancer
EJ Small et al, JCO. Dec 1 2003; 21(23):4277-84
-
A Double-Blind, Placebo-Controlled, Randomized Trial of Oral Sodium Clodronate for Metastatic Prostate Cancer (MRC PR05 Trial)
DP Dearnaley et al, J Natl Cancer Inst. Sep 3 2003; 95(17):1300-11
-
Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate versus Mitoxantrone/Prednisone and Placebo in Patients with Hormone-Refractory Prostate Cancer and Pain
DS Ernst et al, JCO. Sep 2003; 21(17):3335-42
-
Bisphosphonates in Prostate Cancer: Where Are We and Where Should We Go?
F Saad et al, J Natl Cancer Inst, Sep 2003; 95(17):1262-3
-
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients with Hormone-Refractory Metastatic Prostate Carcinoma
F Saad et al, J Natl Cancer Inst. Oct 2 2002; 94(19):1458-68
-
Should Bisphosphonates be Used Routinely in Patients with Prostate Cancer metastatic to Bone?
CM Canil et al, J Natl Cancer Inst. Oct 2 2002; 94(19):1422-32
